| Document |
Document Title |
|
WO/2010/058995A1 |
Provided is an electroluminescent device comprising an organic layer interposed between an anode and a cathode on a substrate, wherein the organic layer includes an electroluminescent layer containing one or more dopant compound (s), and...
|
|
WO/2010/050779A1 |
Provided are novel organic electroluminescent compounds, and organic electroluminescent devices and organic solar cells comprising the same. The organic electroluminescent compounds according to the present invention exhibit high luminou...
|
|
WO/2010/045580A1 |
This disclosure relates to sphingosine-1 -phosphate (SlP) receptor antagonists, compositions comprising the SlP receptor antagonists and methods for using and processes for making the SlP receptor antagonists. In particularly, this discl...
|
|
WO/2010/044054A1 |
The invention relates to novel phenethylamide derivatives and their heterocyclic analogues of formula (I), wherein A, B, R1, R2 and R3 are as described in the application, and to the use of such compounds, or of pharmaceutically acceptab...
|
|
WO/2010/042649A2 |
The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A4, L, R...
|
|
WO/2010/036553A1 |
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein R1, R2, R3, R4, X, Y and m are as defined in the disclosure. Also disclosed are compositions containing the compounds o...
|
|
WO/2010/029379A1 |
The present invention relates to compounds of general formula (i) having an oxime moiety or a pharmaceutically acceptable salt, hydrate or solvate thereof and its use for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also know...
|
|
WO/2010/028051A2 |
The present invention generally relates to substituted heterocyclic mercaptosulfonamide compounds, precursors, and derivatives as well as methods for the preparation of and pharmaceutical compositions comprising these compounds. These co...
|
|
WO/2010/019417A2 |
Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving chymase (formula I). Also disclosed are pharmaceutical compositions, methods of using and making the same.
|
|
WO/2010/006940A1 |
Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein A and R1 to R3 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.
|
|
WO/2010/003624A2 |
Heterocyclic derivatives, processes for their preparation, medicaments comprising these compounds, and the use thereof. The invention relates to compounds of the formula I in which the radicals R1, R2, R3, R4, W, A, B, D, E, G, L, M, R, ...
|
|
WO/2010/004215A2 |
The present invention relates to compounds having the formula (I) where: - R1 is: a substituted or non-substituted phenyl; a substituted or non-substituted naphthyl; a substituted or non-substituted pyridyl; a substituted or non-substitu...
|
|
WO/2010/000456A1 |
The present invention is concerned with novel substituted 6-(1-piperazinyl)-pyridazines of Formula (I) wherein R1, R2, R3 and X have the meaning defined in the claims, having 5 -HT6- antagonistic properties. The invention further relates...
|
|
WO/2009/157425A1 |
Disclosed is a composition comprising a compound having a pyridazine ring structure and a phosphorescent compound.
|
|
WO/2009/146648A1 |
Amide compounds, preparation methods and uses thereof. The structure of the compounds is represented as the general formula (I), in which the definitions of substituents are illuminated as description. The present amide compounds have br...
|
|
WO/2009/141291A1 |
The present invention relates to heteroarylylmethyl sulfonamides of formula (I) wherein B, E, Ra, n, R, A, Y and Cy are as defined in the claims, to the N-oxides, and salts thereof and their use for combating harmful fungi, and also to c...
|
|
WO/2009/136191A1 |
The invention relates to chemical compounds of formula (I): or pharmaceutically acceptable salts thereof which possess CSF-IR kinase inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of tre...
|
|
WO/2009/131947A2 |
The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administerin...
|
|
WO/2009/127338A1 |
The present invention relates to novel carboxylic acid derivates of the formula (I), having an oxo-substituted azaheterocyclic partial structure, method for the production thereof, use thereof for treating and/or preventing illnesses and...
|
|
WO/2009/129267A2 |
Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein.
|
|
WO/2009/124903A1 |
The present invention relates to pyridazinylmethyl sulfonamides of formula (I) wherein Ra, n, R1, R2, R3, A, Y and Het are as defined in the claims, to the N-oxides, and salts thereof and their use for combating harmful fungi, and also t...
|
|
WO/2009/079797A9 |
The invention relates to a compound of Formula (I) and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, E-isomer, Z-isomer, or combination thereof, wherein X is selected from S or O; R5 is selected from ...
|
|
WO/2009/114994A1 |
Derivatives of 6-(3-(trifluoromethyl)phenyl)pyridazin-3(2H)-one having the following formula (I) are used for the manufacture of medicament for anti-tumour, particularly anti-liver cancer.
|
|
WO/2009/114993A1 |
Pyridazinones of formula I, which have a mother nucleus of 6-[3-(trifluoromethyl)phenyl] pyridazin-3(2H)-one, the preparation and the use in manufacturing medicaments of treating tumor thereof. Particularly, the use of such compounds in ...
|
|
WO/2009/112461A1 |
This invention relates to novel triaryl derivatives derivatives, formula (I), a stereoisomer thereof or a mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof, wherein all of X, Y and Z represent CH; or one or two ...
|
|
WO/2009/103478A1 |
The present invention relates to pyridone and pyridazinone derivatives as listed in claim 1 including their salts. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention....
|
|
WO/2009/097306A1 |
The present invention is directed to compounds having histamine H3 antagonist activity, as well as methods of their use and preparation.
|
|
WO/2009/086041A1 |
Disclosed are compounds of Formula (1), N-oxides, and salts thereof, wherein W1 is O or S, and R1, R2, R3, G and J are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula (1) and methods for ...
|
|
WO/2009/080314A1 |
The present invention relates to novel pyridazine derivatives of formula (I) as active ingredients which have microbiocidal activity, in particular fungicidal activity: formula (I) wherein R1 is C1-C6alkyl, C1-C6haloalkyl or C3-C6cycloal...
|
|
WO/2009/071448A1 |
The present invention relates to novel pyridylmethyl-sulfonamide compounds of formula (I) where: n is 0 to 4; m is 0 to 4; R1 is halogen, CN, NO2, OH, SH, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, etc.; and/or two rad...
|
|
WO/2009/071449A1 |
The present invention relates to novel pyridylmethyl-sulfonamide compounds of formula (I): where: n is 0 to 4; m is 0 to 4; R1 is halogen, CN, NO2, OH, SH, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, etc.; and/or two ra...
|
|
WO/2009/056692A2 |
The invention relates to novel products of formula (I): where ---- is a single or double bond, Ra = H, HaI, alkoxy, O-cycloalkyl, heteroaryl,.phenyl, NHCOaIk, NHCOcycloalk or NR1 R2; X = S, SO or SO2; A = NH or S; W = H, alkyl or COR wit...
|
|
WO/2009/057827A1 |
Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.
|
|
WO/2009/053799A1 |
The present invention relates to compounds of f formula (I) as cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2 ) receptor modulators, and uses thereof f or treating diseases, conditions and/or dis...
|
|
WO/2009/050469A1 |
4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro
-benzyl]-2H-phthalazin-1-one as crystalline Form L, methods of obtaining form L, pharmaceutical compositions comprising Form L and methods of using Form L and compositions comp...
|
|
WO/2009/048864A1 |
Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-metho
xybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and salts thereof are disclosed.
|
|
WO/2009/048101A1 |
Disclosed is a novel fused ring compound, which has FAAH inhibitory activity and is useful as an analgesic. Specifically disclosed is a compound represented by the formula (I) below or a salt thereof. (In the formula, the symbols are as ...
|
|
WO/2009/040288A1 |
The present invention relates to compounds of formula (1), wherein A, n, R1a to R1e and R2 to R5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antag...
|
|
WO/2009/037394A2 |
The invention relates to 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]pyridazine derivatives of general formula (I) where R2 = an optionally substituted aryl, A = optionally substituted C1-7 alkylene, B = optionally substituted C1-7 alky...
|
|
WO/2009/035150A2 |
There is provided a compound represented by the formula (I): wherein R1 is a C1-6 alkyl group or a (C1-6 alkyloxy)C1-6 alkyl group; R2 is a hydrogen atom or a C1-6 alkyl group; G is a hydrogen atom etc.; Z1 is a C1-6 alkyl group or a C1-...
|
|
WO/2009/030715A1 |
The invention relates tosubstitutedarylsulphonylaminomethylphosphonic acid derivativesof general formula (I) wherein the groups Ra to Rf, A and Z are defined as mentioned in the specification and claims, which are suitable for preparinga...
|
|
WO/2009/032277A1 |
This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (I). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the c...
|
|
WO/2009/027450A1 |
The invention relates to compounds of general formula (I), in which n, R1, R2, R3, R4, R5, R6, R7 and R8 are defined as cited in the description, to the enantiomers, diastereomers, mixtures and salts of said compounds, in particular to t...
|
|
WO/2009/027730A1 |
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP- ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory di...
|
|
WO/2009/024221A1 |
Compounds of the formula I in which R1, R2 and R3 have the definitions stated in claim 1 are inhibitors of tyrosine kinases, more particularly of Met kinase, and can be used for purposes including the treatment of tumours.
|
|
WO/2009/016286A2 |
The invention relates to the 6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives corresponding to general formula (I), in which formula (I) R2 is an aryl group optionally substituted with one or more substituents chosen fro...
|
|
WO/2009/007856A2 |
The present invention provides a novel polymorphic form of atorvastatin calcium, designated as form Al, process for preparation, pharmaceutical compositions, and method of treating thereof. The present invention further provides a proces...
|
|
WO/2009/004356A1 |
A compound of the formula (I): wherein: R represents one or more optional substituents on the fused cyclohexene ring; X can be NRX or CRXRY; if X = NRX then n is 1 or 2 and if X = CRXRY then n is 1; if X = NRX, then RX is selected from t...
|
|
WO/2008/156208A1 |
The object is to find a compound having an inhibitory activity on the production of PAI-1, an inhibitory activity on the fibrosis of a tissue and a fibrinolytic activity, and to provide a novel compound useful for the prevention and/or t...
|
|
WO/2008/146914A1 |
A compound represented by the formula: (I) (wherein the ring A represents pyrimidine or the like, the ring B represents a carbocyclic ring which may be substituted, an aromatic heterocyclic ring which may be substituted or an alicyclic h...
|
